Skip to main content

5 Result(s)

within Rashmi Mehta Remove this filter Pharmacotherapy Remove this filter

and

  1. Article

    Open Access

    Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

    Population pharmacokinetic methods were used to characterize the pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (C...

    Rashmi Mehta, Colm Farrell, Siobhán Hayes, Ruby Birk… in Clinical Pharmacokinetics (2020)

    Download PDF (1846 KB) View Article

  2. No Access

    Article

    Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler

    The Rotacaps®/Rotahaler® system is a single unit dose inhaler being developed to deliver inhaled salmeterol/fluticasone propionate combination (SFC) as an alternative treatment option to the metered dose inhaler ...

    Rashmi Mehta, Kylie Riddell, Ashutosh Gupta… in Clinical Drug Investigation (2015)

  3. No Access

    Article

    Population Pharmacokinetics of Inhaled Umeclidinium and Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

    A fixed-dose combination of the bronchodilators umeclidinium and vilanterol is in development for the long-term, once-daily treatment of chronic obstructive pulmonary disease (COPD). We characterized the pharm...

    Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church… in Clinical Pharmacokinetics (2014)

  4. No Access

    Article

    Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Inhaled Once-Daily Umeclidinium in Healthy Adults Deficient in CYP2D6 Activity: A Double-Blind, Randomized Clinical Trial

    Umeclidinium is a new, long-acting, muscarinic receptor antagonist currently in development for the treatment of chronic obstructive pulmonary disease (COPD). In vitro cell culture data suggest that up to 99 %...

    Anthony Cahn, Rashmi Mehta, Andrew Preece, James Blowers… in Clinical Drug Investigation (2013)

  5. No Access

    Article

    Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies

    Chronic obstructive pulmonary disease (COPD) has a significant negative impact on quality of life and increases the risk of premature death. Umeclidinium is a long-acting muscarinic receptor antagonist in deve...

    Anthony Cahn, Ruth Tal-Singer, Isabelle J. Pouliquen… in Clinical Drug Investigation (2013)